Worldwide assessment of the activity of cefotetan against clinical isolates.
Data on the antibacterial activity of cefotetan collected since 1985 have been compiled into a computer database and an analysis of results on more than 100,000 clinical isolates presented. The studies were conducted in 285 hospitals located throughout Europe, South Africa, Australia and the USA. The results demonstrate the effectiveness of cefotetan as a broad spectrum agent with significant activity against clinically important aerobes and anaerobes. This is exemplified by the susceptibility to cefotetan of 92% of 14,315 strains of Staphylococcus aureus, 99% of 24,103 strains of Escherichia coli and 93% of 1,841 strains of Bacteroides fragilis.
Turner
P J
PJ
Antibiotic Development, ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, England.
Edwards
J R
JR
D015313:Cefotetan / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D005839:Gentamicins / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D007256:Information Systems; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology
D002511:Cephalosporins; D005839:Gentamicins; D008795:Metronidazole; D002981:Clindamycin; D015313:Cefotetan; D010878:Piperacillin